Research programme: Dolaflexin antibody-drug conjugates - Merck KGaA/ Mersana Therapeutics

Alternative Names: antibody-drug conjugates- Dolaflexin

Latest Information Update: 12 Mar 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

15 Dec 2023 Merck and Mersana Therapeutics terminates their collaboration and commercial license agreement to develop novel immunostimulatory antibody-drug conjugates
26 Sep 2023 Preclinical trials in Unspecified in USA (unspecified route) (Mersana Therapeutics pipeline, September 2023)
28 Mar 2023 Mersana Therapeutics has patent protection for antibody-drug conjugates (ADCs) utilising the Fleximer® polymer in the US

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com